All In Biotech

Drug Trial Radar · NCT07932808

Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma

A Beat Childhood Cancer Research Consortium Phase II Trial of Transplant-Free Chemo-immunotherapy Consolidation Regimen With Naxitamab for High-Risk Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

101

Planned (sponsor's estimate)

Start

Nov 26, 2026

Primary completion

Nov 26, 2031

Study completion Nov 26, 2040

Sponsor

Lead sponsor
Giselle ShollerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SERB Pharmaceuticals
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.

Conditions

  • Neuroblastoma

Interventions

  • Naxitamab and GM-CSF in combination with irinotecan and temozolomideDrug

    anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation

  • Dinutuximab. ImmunotherapyDrug

    Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) for 5 cycles plus Isotretinoin alone in Cycle 6

  • DFMODrug

    DFMO Monotherapy: DFMO for 730 days (2 years)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of days that subjects remain in event freeTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.